Trial Profile
A prospective, open-label, single-centre, (randomized) study to assess the safety, pharmacokinetics, and pharmacodynamics of daily doses of metyrapone given to patients with adrenocortical incidentaloma and sub-clinical Cushing's syndrome
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Jun 2016
Price :
$35
*
At a glance
- Drugs Metyrapone (Primary)
- Indications Adrenocortical carcinoma; Cushing syndrome
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors HRA Pharma
- 22 Jan 2014 Planned number of patients changed from 26 to 9 as per United Kingdom Clinical Research Network record.
- 01 Nov 2013 New trial record